Oncolytics Biotech Inc. - Common Stock (TSX:ONC)

1.420 UNCHANGED

Last Price Updated: 4:00 PM EDT, Aug 22, 2025 Add to My Watchlist

Price and Volume

Volume	0
Open	1.420
Bid (Size)	1.390 (14)
Ask (Size)	1.420 (20)
Prev. Close	1.420
Today's Range	1.420 - 1.420
52wk Range	1.420 - 1.420
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies

July 08, 2025

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:MBIO),(NASDAQ:VSTM),(NASDAQ:CRDF),(NASDAQ:AZN) EQNX::TICKER_END

Via FinancialNewsMedia

Oncolytics Biotech® Highlights Transformative Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies

July 08, 2025

Comparison with multiple landmark first-line metastatic pancreatic ductal adenocarcinoma studies substantiates strong two-year survival benefit of 21.9% vs. 9.2% historical benchmark Consistent...

Via FinancialNewsMedia

Performance

More News

Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies

July 08, 2025

From FN Media Group LLC

Via GlobeNewswire

The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough

June 26, 2025

Via FinancialNewsMedia

Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices

June 24, 2025

Via FinancialNewsMedia

Cancer Rates Are Surging in Young Adults — Here’s Where the Smart Money Is Going

June 18, 2025

Via FinancialNewsMedia

Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven by Increasing Cancer Incidences

June 11, 2025

Via FinancialNewsMedia

Oncolytics Biotech® Names New CEO to Accelerate Momentum in Immunotherapy Programs

June 11, 2025

Via FinancialNewsMedia

Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven by Increasing Cancer Incidences

June 11, 2025

From FN Media Group LLC

Via GlobeNewswire

Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer

February 18, 2025

Via FinancialNewsMedia

Optimism in War on Cancer on the Rise, as Biotech Companies Roll Out More Wins

February 18, 2025

Via FinancialNewsMedia

Oncolytics Biotech® to Present Compelling New Efficacy and Safety Data in Anal and Pancreatic Cancers at 2025 ASCO GI Symposium

January 22, 2025

Via FinancialNewsMedia

Regulatory Approval Clears Path for Oncolytics Biotech® to Advance Promising Pancreatic Cancer Treatment, Following a Review of Safety Data

January 15, 2025

Via FinancialNewsMedia

Demand for Advanced Pancreatic Cancer Treatments at All Time High as Promising Options Come into Focus

January 22, 2025

From FN Media Group LLC

Via GlobeNewswire

Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook

December 26, 2024

Via FinancialNewsMedia

Oncolytics Biotech® Highlights 2024 Achievements and Prepares for an Influential 2025 with Promising Breast and GI Cancer Data

December 26, 2024

Via FinancialNewsMedia

Oncology Advancements Accelerate Amid Rising Early-Onset Cancer Diagnoses

December 20, 2024

Via FinancialNewsMedia

Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook

December 26, 2024

From FN Media Group LLC

Via GlobeNewswire

Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers

December 18, 2024

Via FinancialNewsMedia

Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers

December 18, 2024

From FN Media Group LLC

Via GlobeNewswire

Oncolytics Biotech® to Present Promising Pelareorep Data in Pancreatic and Anal Cancers at ASCO GI Symposium

December 18, 2024

Via FinancialNewsMedia

Active Biotech Alert: FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket

October 04, 2024

Via FinancialNewsMedia

Oncolytics Biotech® Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study

September 20, 2024

Via FinancialNewsMedia

How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs

September 20, 2024

Via FinancialNewsMedia

How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs

September 20, 2024

From FN Media Group LLC

Via GlobeNewswire

Frequently Asked Questions

Is Oncolytics Biotech Inc. - Common Stock publicly traded?

Yes, Oncolytics Biotech Inc. - Common Stock is publicly traded.

What exchange does Oncolytics Biotech Inc. - Common Stock trade on?

Oncolytics Biotech Inc. - Common Stock trades on the Toronto Stock Exchange

What is the ticker symbol for Oncolytics Biotech Inc. - Common Stock?

The ticker symbol for Oncolytics Biotech Inc. - Common Stock is ONC on the Toronto Stock Exchange

What is the current price of Oncolytics Biotech Inc. - Common Stock?

The current price of Oncolytics Biotech Inc. - Common Stock is 1.420

When was Oncolytics Biotech Inc. - Common Stock last traded?

The last trade of Oncolytics Biotech Inc. - Common Stock was at 08/22/25 04:00 PM ET